Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

US8492328B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Fei Huang · Shanghai, CN
• Xia Han · Pennington, US
• Rameh Hafezi · Willingboro, US
• Jiwen Chen · Bound Brook, US
• Douglas Michael Robinson · Hanover, US
• Gayle M. Wittenberg · Plainsboro, US
• Ashok Ramesh Dongre · Newtown, US
• Joan Carboni · Yardley, US
• Ricardo Attar · Lawrenceville, US
• Warren Hurlburt · Mount Laurel, US
• Marco Gottardis · Princeton, US

Key dates

• Filing date: May 15, 2008
• Grant date: Jul 23, 2013
• Expiry date: Aug 24, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.